As of 2025-07-15, the EV/EBITDA ratio of Reata Pharmaceuticals Inc (RETA) is -15.37. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RETA's latest enterprise value is 5,813.45 mil USD. RETA's TTM EBITDA according to its financial statements is -378.12 mil USD. Dividing these 2 quantities gives us the above RETA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 13.1x | 10.8x |
| Forward P/E multiples | 11.4x - 17.5x | 14.9x |
| Fair Price | (128.61) - (147.75) | (145.10) |
| Upside | -174.6% - -185.7% | -184.2% |
| Date | EV/EBITDA |